<DOC>
	<DOCNO>NCT02416271</DOCNO>
	<brief_summary>The main purpose study evaluate effect teriparatide alendronate spine bone mineral density ( BMD ) osteoporosis factor postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>The Forteo Alendronate Comparator Trial</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal woman osteoporosis . Ambulatory , 5 year past menopause . BMD T score 2.5 4.0 lumbar spine femoral neck . Normal clinically insignificant abnormal laboratory value , include serum calcium , parathyroid hormone ( PTH ) 184 , 25hydroxyvitamin D , alkaline phosphatase . Prior treatment PTH PTH analogue . Treatment bisphosphonates within 12 month , anabolic corticosteroid calcitriol vitamin D analogue agonist within 6 month , estrogens selective estrogen receptor modulators within 3 month , calcitonin within 2 month ; therapeutic dos fluoride ; systemic corticosteroid use within 1 month 30 day prior year ; use anticoagulant within 1 month . History disease postmenopausal osteoporosis affect bone metabolism . History increase risk osteosarcoma ( ie , patient Paget disease bone , previous skeletal exposure external beam radiotherapy , previous malignant neoplasm involve skeleton ) . Malignant neoplasm within 5 year ; carcinoma situ uterine cervix within 1 year . Nephrolithiasis urolithiasis within 2 year , impair renal function . Abnormal uncorrected thyroid function . Liver disease clinical jaundice . Alcohol drug abuse . Poor medical psychiatric risk treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>